|Bid||53.29 x 900|
|Ask||53.48 x 800|
|Day's Range||52.37 - 58.91|
|52 Week Range||7.61 - 65.43|
|Beta (5Y Monthly)||1.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 02, 2020 - Nov. 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||76.75|
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
The FDA accepts ChemoCentryx's (CCXI) NDA for avacopan, for the treatment of ANCA-associated vasculitis.